Article Text

Download PDFPDF

Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?
Free
  1. D E Newby1,
  2. S J Cowell1,
  3. N A Boon1
  1. Department of Cardiology, Royal Infirmary, Edinburgh, UK
  1. Correspondence to:
    Professor David E Newby
    Room SU314, Chancellor’s Building, Royal Infirmary, 49 Little France Crescent, Edinburgh EH16 4SB, UK; d.e.newby{at}ed.ac.uk

Abstract

Aortic stenosis is the most common adult heart valve condition seen in the Western world and its incidence continues to rise. No established disease modifying treatments retard progression of the stenotic process. Recent insights into the pathogenesis of calcific aortic stenosis suggest that the disease mimics atherosclerosis. The natural history and progression of calcific aortic stenosis are described with particular emphasis on new and emerging medical treatments that may modify the disease process. In particular, statins and angiotensin converting enzyme inhibitors appear to hold promise but definitive evidence from large clinical trials is awaited.

  • ACE, angiotensin converting enzyme
  • ASTRONOMER, aortic stenosis progression observation: measuring effect of rosuvastatin
  • LDL, low density lipoprotein
  • SALTIRE, Scottish aortic stenosis and lipid lowering therapy, impact on regression
  • SEAS, simvastatin and ezetimibe in aortic stenosis
  • aortic stenosis
  • angiotensin converting enzyme inhibitors
  • statins

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Conflicts of interest declaration: The authors were involved in the SALTIRE trial funded by the British Heart Foundation with an additional educational grant award from Pfizer (UK) Limited and are participating in the SEAS study, which is sponsored by Merck Sharp and Dohme Limited.

Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society